Viewing Study NCT07093866


Ignite Creation Date: 2025-12-24 @ 4:32 PM
Ignite Modification Date: 2026-03-08 @ 1:06 AM
Study NCT ID: NCT07093866
Status: RECRUITING
Last Update Posted: 2025-07-30
First Post: 2025-07-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II Study
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module